You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
熱點掃描 | 科技股集體上揚,恆科指數漲超2%

uSMART盈立智投9月20日消息,截止發稿,港股三大指數齊漲,恆生指數漲1.12%,報18773.2點,成交額282.19億;國企指數漲1.19%,報6412.37點,成交額86.39億;紅籌指數漲0.35%,報3620.57點,成交額10.32億。

餐飲股下挫,海底撈跌超4%,九毛九跌超3%,呷哺呷哺、奈雪的茶跌超1%;

蘋果概念股走強,高偉電子漲近5%,比亞迪電子漲2.2%,丘鈦科技漲1%,知名蘋果分析師郭明錤發文指出,由於iPhone 14 Pro的需求強勁,蘋果已要求鴻海將iPhone 14的生產線切換到iPhone 14 Pro機型,相當於將第四季度iPhone 14 Pro出貨量預測提升10%左右;

科技股今日集體上揚,恆生科技指數漲超2%,其中,小鵬汽車漲超8%,理想汽車和蔚來漲超5%,網易漲超4%,金山軟件、京東、美團、阿裏巴巴漲超3%,百度、快手、商湯漲超2%,騰訊漲近2%;

燃料電池板塊持續走高,超威動力漲近5%,東嶽集團、比亞迪股份漲近3%,中集安瑞科、上海電氣漲超1%。

熱門股

榮昌生物一度漲超6%,現報39.25港元,公司昨日宣佈,已完成泰它西普(RC18, 商品名: 泰愛)治療系統性紅斑狼瘡(SLE)患者的國內Ⅲ期確證性研究,並獲得初步數據結果,本研究達到了預設的臨牀終點,第52周SRI-4應答率在泰它西普組爲82.6%,安慰劑組爲38.1%;除系統性紅斑狼瘡適應症外,泰它西普治療類風溼性關節炎、多發性硬化等適應症的Ⅱ/Ⅲ期臨牀研究也在推進中;華泰證券指出,泰它西普SLE 國內III期臨牀達到主要終點,維持“買入”評級;

中船防務現漲6.32%,報7.57港元,9月19日南向資金再度增持中船防務7.40萬股,錄得連續3日增持,公司是中小型軍艦、支線集裝箱船和特種船舶的全球知名的建造企業,中信建投此前指出,公司船價上升疊加公司造船效率提升,將有力提升公司的毛利率和盈利水平。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account